A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

• Status: Completed
• Trial end date: 2012-02-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Analgesics, Opioid; Tanezumab

Criteria

Inclusion Criteria:

• Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has spread to bone, causing moderate to severe bone pain.

• Requires daily opioid medication

Exclusion Criteria:

• Patients who do not have bone pain caused by cancer are not eligible for the study.

• Patients who started chemotherapy less than 4 weeks ago, or who completed radiotherapy less than 4 weeks ago, are not eligible.

• Known history or evidence of osteoarthritis. History of significant trauma to a major joint within 1 year prior to Screening.

• Known history of rheumatoid arthritis.